PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors.

Proceedings of the National Academy of Sciences of the United States of America
Thomas JanuarioRobert L Yauch

Abstract

Subunits of the SWI/SNF chromatin remodeling complex are frequently mutated in human cancers leading to epigenetic dependencies that are therapeutically targetable. The dependency on the polycomb repressive complex (PRC2) and EZH2 represents one such vulnerability in tumors with mutations in the SWI/SNF complex subunit, SNF5; however, whether this vulnerability extends to other SWI/SNF subunit mutations is not well understood. Here we show that a subset of cancers harboring mutations in the SWI/SNF ATPase, SMARCA4, is sensitive to EZH2 inhibition. EZH2 inhibition results in a heterogenous phenotypic response characterized by senescence and/or apoptosis in different models, and also leads to tumor growth inhibition in vivo. Lower expression of the SMARCA2 paralog was associated with cellular sensitivity to EZH2 inhibition in SMARCA4 mutant cancer models, independent of tissue derivation. SMARCA2 is suppressed by PRC2 in sensitive models, and induced SMARCA2 expression can compensate for SMARCA4 and antagonize PRC2 targets. The induction of SMARCA2 in response to EZH2 inhibition is required for apoptosis, but not for growth arrest, through a mechanism involving the derepression of the lysomal protease cathepsin B. Expression of S...Continue Reading

References

Nov 30, 2000·Proceedings of the National Academy of Sciences of the United States of America·C W RobertsS H Orkin
Apr 21, 2001·Molecular and Cellular Biology·C J GuidiS N Jones
Mar 7, 2003·Molecular Cell·Shilpa Kadam, Beverly M Emerson
May 17, 2008·Cancer Research·Selina GlarosDavid Reisman
Jan 16, 2009·The Journal of Biological Chemistry·Stephen FlowersElizabeth Moran
Dec 5, 2012·Cancer Discovery·Jennifer N Wu, Charles W M Roberts
Apr 27, 2013·Proceedings of the National Academy of Sciences of the United States of America·Sarah K KnutsonHeike Keilhack
Jan 15, 2014·Molecular and Cellular Biology·Boris G WilsonCharles W M Roberts
Feb 13, 2014·Proceedings of the National Academy of Sciences of the United States of America·Gregory R HoffmanZainab Jagani
Mar 25, 2014·Nature Genetics·Petar JelinicDouglas A Levine
Apr 23, 2014·The Journal of Pathology·William D FoulkesW Glenn McCluggage
Jun 11, 2014·Oncotarget·Bhaskar KahaliDavid Reisman
Aug 30, 2014·American Journal of Medical Genetics. Part C, Seminars in Medical Genetics·Jaclyn A BiegelBernard E Weissman
Nov 12, 2014·Annual Review of Pathology·Julien Masliah-PlanchonOlivier Delattre
Feb 17, 2015·Nature Medicine·Benjamin G BitlerRugang Zhang
Nov 10, 2015·Nature Medicine·Kimberly H KimCharles W M Roberts
Feb 3, 2016·Biochemistry·Cigall KadochHeike Keilhack
Nov 4, 2016·Nature Reviews. Cancer·Itys CometKristian Helin
Dec 13, 2016·Nature Genetics·Radhika MathurCharles W M Roberts

❮ Previous
Next ❯

Citations

Aug 7, 2019·International Journal of Surgical Pathology·Brian D StewartPetr Starostik
Jan 30, 2020·Journal of Cutaneous Pathology·Bruce D LeckeyRami N Al-Rohil
Feb 1, 2019·British Journal of Haematology·Matthew J Barth, Veronique Minard-Colin
Mar 23, 2019·Epigenetics & Chromatin·Amelie AlfertKornelius Kerl
Jan 30, 2019·Cell Death and Differentiation·Swathi RamakrishnanAnna Woloszynska
Jun 30, 2018·Nature Reviews. Clinical Oncology·Alan Ashworth, Christopher J Lord
Apr 16, 2019·Expert Review of Anticancer Therapy·Krystal A OrlandoBernard E Weissman
Nov 14, 2019·Cancers·Pooja PanditaShannon M Hawkins
Oct 31, 2020·The Journal of Pathology. Clinical Research·Basile Tessier-CloutierCheng-Han Lee
Apr 10, 2020·Archives of Pathology & Laboratory Medicine·Aruna NambirajanDeepali Jain
Jul 25, 2018·Molecular Cancer Research : MCR·Takeshi FukumotoRugang Zhang
Aug 9, 2020·Molecular Cell·Roger D Kornberg, Yahli Lorch
Aug 2, 2020·Seminars in Cancer Biology·Ammad Ahmad FarooqiMassimo Mallardo
Nov 22, 2019·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Natasha RekhtmanWilliam D Travis
Feb 9, 2021·The American Journal of Pathology·Talha AnwarCelina G Kleer
Dec 29, 2020·Archives of Pathology & Laboratory Medicine·Aruna NambirajanDeepali Jain
Mar 29, 2018·Cell Reports·Takeshi FukumotoRugang Zhang
Apr 14, 2021·Nucleic Acids Research·Dongxue SuLin Shan
Jun 4, 2021·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Christopher J SchwartzHannah Y Wen
May 14, 2021·The FEBS Journal·Marton Siklos, Stefan Kubicek
Jan 16, 2022·Proceedings of the National Academy of Sciences of the United States of America·Yiji LiaoKexin Xu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Cancer Epigenetics Chromatin Complexes (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin complexes and their role in cancer epigenetics.

Cancer Epigenetics and Chromatin (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin and its role in cancer epigenetics please follow this feed to learn more.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.